82990
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 3
- fusion
- other ZFTA
- e1_e2
- E1
- umap1_2d
- -3.621485
- umap2_2d
- 2.89373081
- umap1_3d
- -0.593579457
- umap2_3d
- 2.72370139
- umap3_3d
- -0.819745039
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.400
- NOTCH_SIGNALING+0.340
- P53_PATHWAY+0.320
- MYC_TARGETS_V2+0.290
- DNA_REPAIR+0.270
- PANCREAS_BETA_CELLS+0.260
- ANGIOGENESIS+0.250
- MYOGENESIS+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
- HYPOXIA+0.240
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.470
- INTERFERON_GAMMA_RESPONSE-0.340
- FATTY_ACID_METABOLISM-0.260
- IL6_JAK_STAT3_SIGNALING-0.180
- ANDROGEN_RESPONSE-0.170
- ALLOGRAFT_REJECTION-0.160
- PROTEIN_SECRETION-0.160
- SPERMATOGENESIS-0.160
- HEME_METABOLISM-0.140
- INFLAMMATORY_RESPONSE-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-6798-01A-11R-1949-07 | — | cohortSQ2 | 0.765 |
| 2 | TCGA-60-2708-01A-01R-0851-07 | — | cohortSQ1 | 0.757 |
| 3 | TCGA-34-5236-01A-21R-1820-07 | — | cohortSQ1 | 0.740 |
| 4 | TCGA-39-5019-01A-01R-1820-07 | — | cohortSQ2 | 0.735 |
| 5 | BS_K3ER45RV | Med | Medulloblastoma | 0.735 |
| 6 | TCGA-CR-5247-01A-01R-2016-07 | — | — | 0.725 |
| 7 | 21e66f0f-e49d-4e75-bc70-f1d248c1b947 | — | — | 0.719 |
| 8 | 620f38f7-7f22-41f3-a478-445f949006fe | — | — | 0.715 |
| 9 | R108 | — | — | 0.713 |
| 10 | TCGA-85-A4CN-01A-11R-A24H-07 | — | cohortSQ2 | 0.707 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.320 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |